Alpa Laboratories Limited AI Stock Analysis
Want to see IN:ALPA full AI Analyst Report?
Alpa Laboratories Limited (ALPA) AI Stock Analysis
Alpa Laboratories Limited
(NSE:ALPA)
The overall score reflects a strong, low-debt balance sheet and reasonable long-term profitability, offset by clearly weakening operating margins, mixed cash conversion, soft price momentum below key moving averages, and a relatively high earnings multiple without visible dividend support.
Alpa Laboratories Limited (ALPA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.05B
- Dividend Yield
- ―
- Average Volume (3M)
- 4,260
- Price to Earnings (P/E)
- 66.6
- Beta (1Y)
- 1.20
- Revenue Growth
- 3.51%
- EPS Growth
- -87.03%
- Country
- India
- Employees
- 457
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Alpa Laboratories Limited Business Overview & Revenue Model
Company Description
Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-gra...
Alpa Laboratories Limited Financial Statement Overview
Summary
Financial strength is solid due to a very conservative balance sheet and consistent equity growth, but deteriorating gross and operating margins plus uneven free cash flow keep the overall financial performance only moderately above average.
Income Statement
63PositiveBalance Sheet
82Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16B | 1.06B | 1.12B | 1.09B | 924.10M | 1.11B |
| Gross Profit | 243.95M | 136.09M | 193.99M | 188.90M | 307.44M | 344.08M |
| EBITDA | 75.79M | 190.47M | 281.01M | 229.96M | 174.43M | 214.31M |
| Net Income | 43.78M | 150.10M | 195.03M | 167.76M | 125.83M | 140.92M |
Balance Sheet | ||||||
| Total Assets | 0 | 2.42B | 2.23B | 1.82B | 1.67B | 1.55B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.38B | 1.13B | 928.54M | 808.42M | 702.74M |
| Total Debt | 0 | 25.08M | 343.00K | 52.47M | 23.04M | 58.47M |
| Total Liabilities | -1.86B | 558.64M | 511.59M | 304.62M | 326.92M | 335.08M |
| Stockholders Equity | 1.86B | 1.86B | 1.71B | 1.52B | 1.35B | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | 89.97M | 84.84M | -21.42M | -27.36M | 77.78M | 77.49M |
| Operating Cash Flow | 106.65M | 124.37M | 92.37M | 36.49M | 89.04M | 99.40M |
| Investing Cash Flow | -144.58M | -143.01M | -35.13M | -133.36M | 21.27M | -156.10M |
| Financing Cash Flow | 22.40M | 24.80M | -52.47M | 25.83M | -37.93M | 54.42M |
Alpa Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Negative. The current price of 49.97 is below the 20-day moving average (MA) of 52.50, below the 50-day MA of 56.19, and below the 200-day MA of 63.98, indicating a bearish trend. The MACD of -1.15 indicates Positive momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALPA.
Alpa Laboratories Limited Peers Comparison
Overall Rating
IN:PAR73Outperform
IN:ALPA63Neutral
IN:BROOKS61Neutral
IN:BALPHARMA58Neutral
IN:BIOFILCHEM58Neutral
IN:NECLIFE43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.40B | 10.61 | ― | ― | 9.40% | 34.12% | |
| 63Neutral | INR 1.06B | 66.56 | ― | ― | 3.51% | -87.03% | |
| 61Neutral | INR 1.99B | 2.71 | ― | ― | -14.88% | 431.30% | |
| 58Neutral | INR 1.35B | 16.71 | ― | 1.43% | 18.79% | -2.58% | |
| 58Neutral | INR 483.49M | 99.32 | ― | ― | 9.31% | -82.71% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 43Neutral | INR 1.94B | -2.89 | ― | ― | -99.85% | 78.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ALPA | Alpa Laboratories Limited | 49.97 | -27.16 | -35.21% | |
| IN:BALPHARMA | Bal Pharma Limited | 83.50 | 8.84 | 11.84% | |
| IN:BIOFILCHEM | Biofil Chemicals & Pharmaceuticals Ltd. | 30.72 | -7.28 | -19.16% | |
| IN:BROOKS | Brooks Laboratories Limited | 67.29 | -28.91 | -30.05% | |
| IN:NECLIFE | Nectar Lifesciences Ltd. | 9.90 | -4.18 | -29.69% | |
| IN:PAR | Par Drugs and Chemicals Limited | 112.06 | 20.46 | 22.34% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026
